Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 1/2014

Open Access 01-02-2014

Changes in Plasma Kynurenic Acid Concentration in Septic Shock Patients Undergoing Continuous Veno-Venous Haemofiltration

Authors: Wojciech Dabrowski, Tomasz Kocki, Jacek Pilat, Jolanta Parada-Turska, Manu L. N. G. Malbrain

Published in: Inflammation | Issue 1/2014

Login to get access

Abstract

Kynurenic acid (KYNA) is one of the end products of tryptophan metabolism. The aim of this study was to analyse plasma KYNA concentration in septic shock patients (SSP) with acute kidney injury (AKI) undergoing continuous veno-venous haemofiltration (CVVH). Changes in KYNA content were compared to alterations in the levels of procalcitonin (PCT), C-reactive protein and lactate. Adult SSP with AKI were examined. Measurements were conducted at seven time points: before beginning CVVH and at 6, 12, 24, 48, 72 and 96 h after the beginning of CVVH. Based on clinical outcomes, the data were analysed separately for survivors and non-survivors. Twenty-seven patients were studied. CVVH was associated with reduced plasma KYNA concentration only in survivors. Plasma KYNA concentration correlated with the levels of lactate and PCT only in survivors. (1) CVVH reduced plasma KYNA concentration only in survivors; (2) lack of this reduction may predict fatal outcomes in SSP.
Literature
1.
Tan, P.H., and A.K. Bharath. 2009. Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases. Expert Opinion on Therapeutic Targets 13: 987–1012.PubMedCrossRef
2.
Zeden, J.P., G. Fusch, B. Holtfreter, J.C. Schefold, P. Reinke, G. Domanska, J.P. Haas, M. Gruendling, A. Westerholt, and C. Schuett. 2010. Excessive tryptophan catabolism along the kynurenine pathway precedes ongoing sepsis in critically ill patients. Anaesthesia and Intensive Care 38: 307–316.PubMedCrossRef
3.
Yeung, A.W., W. Wu, M. Freewan, R. Stocker, N.J. King, and S.R. Thomas. 2012. Flavivirus infection induces indoleamine 2,3-dioxygenase in human monocyte-derived macrophages via tumor necrosis factor and NF-κB. Journal of Leukocyte Biology 91: 657–666.PubMedCrossRef
4.
Schefold, J.C., J.P. Zeden, R. Pschowski, B. Hammoud, C. Fotopoulou, D. Hasper, G. Fusch, S. Von Haehling, H.D. Volk, C. Meisel, C. Schütt, and P. Reinke. 2010. Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. Scandinavian Journal of Infectious Diseases 42: 164–171.PubMedCrossRef
5.
O'Connor, J.C., C. Andre, Y. Wang, M.A. Lawson, S.S. Szegedi, J. Lestage, N. Castanon, K.W. Kelly, and R. Dantzer. 2009. Interferon gamma and tumor necrosis factor alpha mediate the upregulation of indoleamine 2,3-dioxygenase and induction of depressive—like behaviour in mice in response to bacillus Calmette-Guerin. Journal of Neuroscience 29: 4200–4209.PubMedCrossRef
6.
Baran, H., G. Amann, B. Lubec, and G. Lubec. 1997. Kynurenic acid and kynurenine aminotransferase in heart. Pediatric Research 41: 404–410.PubMedCrossRef
7.
Noguchi, T., Y. Minatogawa, E. Okuno, M. Nakatani, M. Morimoto, and R. Kido. 1975. Purification and characterization of kynurenine-2-oxoglutarate aminotransferase from the liver, brain and small intestine of rats. Biochemistry Journal 151: 399–406.CrossRef
8.
Stazka, J., P. Luchowski, M. Wielosz, Z. Kleinrok, and E.M. Urbanska. 2002. Endothelium-dependent production and liberation of kynurenic acid by rat aortic rings expose to L-kynurenine. European Journal of Pharmacology 448: 133–137.PubMedCrossRef
9.
Ploder, M., A. Spittler, K. Schroecksanadel, G. Neurauter, L.E. Pelinka, E. Roth, and D. Fuchs. 2009. Tryptophan degradation in multiple trauma patients: survivors compared with non-survivors. Clinical Science 116: 593–598.PubMedCrossRef
10.
Lögters, T.T., M.D. Laryea, J. Altrichter, J. Sokolowski, J. Cinati, J. Reipen, W. Linhart, J. Windolf, M. Scholz, and M. Wild. 2009. Increased plasma kynurenine values and kynurenine-tryptophan ratios after major trauma are early indicators for the development of sepsis. Shock 32: 29–34.PubMedCrossRef
11.
Maes, M., I. Mihaylova, M.D. Ruyter, M. Kubera, and E. Bosmans. 2007. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression—and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinology Letters 28: 826–831.PubMed
12.
Jung, I.D., M.G. Lee, J.H. Chang, J.S. Lee, Y.I. Jeong, C.M. Lee, W.S. Park, J. Han, S.K. Seo, S.Y. Lee, and Y.M. Park. 2009. Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock. Journal of Immunology 182: 3146–3154.CrossRef
13.
Mándi, Y., and L. Vécsei. 2012. The kynurenine system and immunoregulation. Journal of Neural Transmission 119: 197–209.PubMedCrossRef
14.
Kaszaki, J., Z. Palásthy, D. Érces, A. Rácz, C. Torday, G. Varga, L. Vécsei, and M. Boros. 2008. Kynurenine acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs. Neurogastroenterology and Motility 20: 53–62.PubMed
15.
Tiszlavicz, Z., B. Németh, F. Fülöp, L. Vécsei, K. Tápai, I. Ocsovszky, and Y. Mándi. 2011. Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils. Naunyn-Schmiedeberg's Archives of Pharmacology 383: 447–455.PubMedCrossRef
16.
Laupland, K.B., H.D. Davies, D.L. Church, T.J. Louie, J.S. Dool, D.A. Zygun, and C.J. Doig. 2004. Bloodstream infection-associated sepsis and septic shock in critically ill adults: a population-based study. Infection 32: 59–64.PubMedCrossRef
17.
Angus, D.C., W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M.R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Critical Care Medicine 29: 1303–1310.PubMedCrossRef
18.
Uzzan, B., R. Cohen, P. Nicolas, M. Cucherat, and G.Y. Perret. 2006. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Critical Care Medicine 34: 1996–2003.PubMedCrossRef
19.
Bellomo, R., D. Mansfield, S. Rumble, J. Shapiro, G. Parkin, and N. Bouce. 1993. A comparison of conventional dialytic therapy and acute continuous hemodiafiltration in the management of acute renal failure in the critically ill. Renal Failure 15: 595–602.PubMedCrossRef
20.
Ronco, C., R. Bellomo, P. Homel, A. Brendolan, M. Dan, P. Piccinni, and G. La Greca. 2000. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomized trial. Lancet 355: 26–30.CrossRef
21.
Peng, Z., P. Pai, L. Hong–Bao, L. Rong, W. Han–Min, and H. Chen. 2010. The impacts of continuous veno-venous hemofiltration on plasma cytokines and monocyte human leukocyte antigen-DR expression in septic patients. Cytokine 50: 186–191.PubMedCrossRef
22.
Heering, P., S. Morgera, F.J. Schmitz, G. Schmitz, R. Willers, H.P. Schultheiss, B.E. Stauer, and B. Grabensee. 1997. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous veno-venous hemofiltration. Intensive Care Medicine 23: 288–296.PubMedCrossRef
23.
Petrovaara, M., A. Raitala, T. Lehtimäki, P.J. Karhunen, S.S. Oja, M. Jalhä, A. Hervonen, and M. Hurme. 2006. Indoleamine 2,3-dioxygenase activity in nonagenarians in markedly increased and predicts mortality. Mechanisms of Ageing and Development 127: 497–499.CrossRef
24.
Huttenen, R., J. Syrjänen, J. Aittoniemi, S.S. Oja, A. Raitala, J. Laine, M. Pertovaara, R. Vuento, H. Huhtala, and M. Hurme. 2010. High activity of indoleamine 2,3 dioxygenase enzume predicts disease severity and case fatality in bacteriemic patients. Shock 33: 149–154.CrossRef
25.
Girgin, G., T.T. Sahin, D. Fuchs, O. Yuksel, O. Kurukahvecioglu, M. Sare, and T. Baydar. 2011. Tryptophan degradation and serum neopterin concentrations in intensive care unit patients. Toxicology Mechanisms and Methods 21: 231–235.PubMedCrossRef
26.
Fukushima, T., S. Mitsuhashi, M. Tomiya, M. Iyo, K. Hashimoto, and T. Toyo'oka. 2007. Determination of kynurenic acid in human serum and its correlation with the concentration of certain amino acids. Clinica Chimica Acta 377: 174–178.CrossRef
27.
Pawlak, D., K. Pawlak, J. Malyszko, M. Mysliwiec, and W. Buczko. 2001. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. International Urology and Nephrology 33: 399–404.PubMedCrossRef
28.
Bone, R.C. 1991. Let's agree on terminology: definitions of sepsis. Critical Care Medicine 19: 973–976.PubMedCrossRef
29.
Ricci, Z., D. Cruz, and C. Ronco. 2008. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney International 73: 538–546.PubMedCrossRef
30.
Osterman, M., H. Dickie, L. Tovey, and D. Trecher. 2010. Heparin algorithm for anticoagulation during continuous renal replacement therapy. Critical Care 14: 419–420.CrossRef
31.
Reintam Blaser, A., M.L. Malbrain, J. Starkopf, S. Fruhwald, S.M. Jakob, J. De Waele, J.P. Braun, M. Poeze, and C. Spies. 2012. Gastrointestinal function in intensive care patients: terminology, definitions and management. Recommendations of the ESICM Working Group on Abdominal Problems. Intensive Care Medicine 38: 384–394.PubMedPubMedCentralCrossRef
32.
Shibata, K. 1988. Fluorimetric micro-determination of kynurenic acid, an endogenous blocker of neurotoxicity, by high-performance liquid chromatography. Journal of Chromatography 430: 376–380.PubMedCrossRef
33.
Turski, W.A., M. Nakamura, W.P. Todd, B.K. Carper Carpenter, W.O. Whetsell Jr., and R. Schwarcz. 1988. Identification and quantification of kynurenic acid in human brain tissue. Brain Research 454: 164–169.PubMedCrossRef
34.
MacKenzie, C.R., K. Heseler, A. Muller, and W. Däubener. 2007. Role of indoleamine 2,3-dioxygenase in antibacterial defense and immuno-regulation: tryptophan depletion versus production of toxic kynurenines. Current Drug Metabolism 8: 237–244.PubMedCrossRef
35.
Bender, D.A. 1983. Biochemistry of tryptophan in health and disease. Molecular Aspects of Medicine 6: 101–197.PubMedCrossRef
36.
Varga, G., D. Érces, B. Fazekas, M. Fülöp, T. Kovács, J. Kaszaki, F. Fülöp, L. Vécsei, and M. Boros. 2010. N-methyl-d-aspartate receptor antagonism decreases motility and inflammatory activation in the early phase of acute experimental colitis in the rat. Neurogastroenterology and Motility 22: 217–225.PubMedCrossRef
37.
Érces, D., G. Varga, B. Fazekas, T. Kovács, T. Tökés, L. Tiszlavicz, F. Fülöp, L. Vécsei, M. Boros, and J. Kaszaki. 2012. N-methyl-d-aspartate receptor antagonist therapy suppresses colon motility and inflammatory activation six days after onset of experimental colitis in rats. European Journal of Pharmacology 691: 225–234.PubMedCrossRef
38.
Asp, L., A.S. Johansson, A. Mann, B. Owe-Larsson, E.M. Urbanska, T. Kocki, M. Kegel, G. Engberg, G.B. Lundkvist, and H. Karlsson. 2011. Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts. Journal of Inflammation 8: 25.PubMedPubMedCentralCrossRef
39.
Stone, T.W., C.M. Forrest, and L.G. Darlington. 2012. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS Journal 279: 1386–1397.CrossRefPubMed
40.
Pawlak, K., A. Kowalewska, M. Myśliwiec, and D. Pawlak. 2009. Kynurenine and its metabolites—kynurenic acid and anthranilic acid are associated with soluble endothelial adhesion molecules and oxidative status in patients with chronic kidney disease. American Journal of the Medical Sciences 338: 293–300.CrossRefPubMed
41.
Schefold, J.C., J.P. Zeden, C. Fotopoulou, S. von Haeling, R. Pschowski, D. Hasper, H.D. Volk, C. Schuett, and P. Reike. 2009. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrology, Dialysis, Transplantation 24: 1901–1908.PubMedCrossRef
42.
Zhao, J. 2013. Plasma kynurenic acid/tryptophan ratio: a sensitive and reliable biomarker for the assessment of renal function. Renal Failure 35: 648–653.PubMedCrossRef
43.
Rhee, E.P., C.B. Clish, A. Ghorbani, M.G. Larson, S. Elmariah, E. McCabe, Q. Yang, S. Cheng, K. Pierce, A. Deik, A.L. Souza, L. Farrell, C. Domos, R.W. Yeh, I. Palacios, K. Rosenfield, R.S. Vasan, J.C. Florez, T.J. Wang, C.S. Fox, and R.E. Gerszten. 2013. A combined epidemiologic and metabolomic approach improves CKD prediction. Journal of the American Society of Nephrology. doi:10.​1681/​ASN.​2012101006.
44.
Saito, K., S. Fujigaki, M. Heyes, K. Shibata, M. Takamura, H. Fujii, H. Wada, A. Noma, and M. Seishima. 2000. Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency. American Journal of Physiology. Renal Physiology 279: F565–F572.PubMedCrossRef
Metadata
Title
Changes in Plasma Kynurenic Acid Concentration in Septic Shock Patients Undergoing Continuous Veno-Venous Haemofiltration
Authors
Wojciech Dabrowski
Tomasz Kocki
Jacek Pilat
Jolanta Parada-Turska
Manu L. N. G. Malbrain
Publication date
01-02-2014
Publisher
Springer US
Published in
Inflammation / Issue 1/2014
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9733-9

Other articles of this Issue 1/2014

Inflammation 1/2014 Go to the issue

OriginalPaper

Honokiol Inhibits Tumor Necrosis Factor-α-Stimulated Rat Aortic Smooth Muscle Cell Proliferation via Caspase- and Mitochondrial-Dependent Apoptosis

OriginalPaper

Hyperleptinemia: Implications on the Inflammatory State and Vascular Protection in Obese Adolescents Submitted to an Interdisciplinary Therapy

OriginalPaper

Serum Analysis of Coagulation Factors in IPF and NSIP

OriginalPaper

Vascular Endothelial Cell Injury Partly Induced by Mesenteric Lymph in Heat Stroke

OriginalPaper

RETRACTED ARTICLE: Release-Active Dilutions of Diclofenac Enhance Anti-inflammatory Effect of Diclofenac in Carrageenan-Induced Rat Paw Edema Model

OriginalPaper

High Asymmetric Dimethylarginine (ADMA) Levels in Patients with Brucellosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits